相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
Tamara L. Lotan et al.
MODERN PATHOLOGY (2021)
SMCHD1 promotes ATM-dependent DNA damage signaling and repair of uncapped telomeres
Aleksandra Vancevska et al.
EMBO JOURNAL (2020)
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
B. Pellegrino et al.
TRANSLATIONAL ONCOLOGY (2020)
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review
Mausam Patel et al.
CELL AND BIOSCIENCE (2020)
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants inBRCA1/2: A Review of Secondary Prevention Guidelines
Boudewijn Dullens et al.
JOURNAL OF ONCOLOGY (2020)
Clinical assays for assessment of homologous recombination DNA repair deficiency
Elizabeth H. Stover et al.
GYNECOLOGIC ONCOLOGY (2020)
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
Emily Nizialek et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy
Rui Gou et al.
LIFE SCIENCES (2020)
Pan-cancer landscape of homologous recombination deficiency
Luan Nguyen et al.
NATURE COMMUNICATIONS (2020)
Regulation and pharmacological targeting of RAD51 in cancer
McKenzie K. Grundy et al.
NAR CANCER (2020)
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
Ethan S. Sokol et al.
JCO PRECISION ONCOLOGY (2020)
Human genes escaping X-inactivation revealed by single cell expression data
Kerem Wainer Katsir et al.
BMC GENOMICS (2019)
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson et al.
NATURE (2019)
Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
Adam Poti et al.
GENOME BIOLOGY (2019)
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Carolyn Hutter et al.
CELL (2018)
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
Paz Polak et al.
NATURE GENETICS (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line
Elias Ellnati et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Kara N. Maxwell et al.
NATURE COMMUNICATIONS (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
Ronglai Shen et al.
NUCLEIC ACIDS RESEARCH (2016)
A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining
Sylvie Moureau et al.
OPEN BIOLOGY (2016)
DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy
Sean P. Pitroda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma
Edmund A. Mroz et al.
ORAL ONCOLOGY (2013)
Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
Nicolai Juul Birkbak et al.
PLOS ONE (2013)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
V. Abkevich et al.
BRITISH JOURNAL OF CANCER (2012)
Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
Tatiana Popova et al.
CANCER RESEARCH (2012)
Absolute quantification of somatic DNA alterations in human cancer
Scott L. Carter et al.
NATURE BIOTECHNOLOGY (2012)
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Nicolai J. Birkbak et al.
CANCER DISCOVERY (2012)
International network of cancer genome projects
Thomas J. Hudson et al.
NATURE (2010)
Allele-specific copy number analysis of tumors
Peter Van Loo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
David A. Barbie et al.
NATURE (2009)
Battle of the BRCA1/BRCA2 (offspring) sex ratios:: truth or consequences
DM Agnese
JOURNAL OF MEDICAL GENETICS (2006)
Inhibition of Atm and/or Atr disrupts gene silencing on the inactive X chromosome
OY Yan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
p53 mutated in the transactivation domain retains regulatory functions in homology-directed double-strand break repair
GS Boehden et al.
ONCOGENE (2003)
Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control
H Willers et al.
ONCOGENE (2000)
分享论文
